Abstract
Aims
We review current models of frailty, describe the design of the FRAILOMIC study, and discuss the advent of the concept of intrinsic capacity as influencing the science of frailty and how this can be clinically interpreted.
Methods
Two main frailty models (Fried Phenotype model; Cumulative Deficit Model) are described and evaluated by detailed literature review. A description of the exploratory phase of the FRAILOMIC initiative is given which resulted in the identification of 13 omic markers related to frailty: these are currently being validated in a validation phase. We then discuss how combining the characteristics of frailty with omic-based biomarkers will enable the development of predictive, diagnostic and prognostic models.
Conclusions
Relating biomarkers associated with frailty to a continuous measure of intrinsic capacity will help in identifying and monitoring at-risk populations. The FRAILOMIC Initiative will provide key insights into the prevention, early detection, and treatment of frailty to reduce the impact of disability in our aging populations.